The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
 
Geoffroy Bilger
No Relationships to Disclose
 
Nicolas Girard
Employment - AstraZeneca (I)
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Lilly; MSD; Novartis; Pfizer; Pharmamar; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; Roche
 
Helene Doubre
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb
Speakers' Bureau - LEO Pharma
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology; Pfizer
 
Matteo Giaj Levra
No Relationships to Disclose
 
Etienne Giroux Leprieur
No Relationships to Disclose
 
Frédérique Giraud
No Relationships to Disclose
 
Chantal Decroisette
Consulting or Advisory Role - AstraZeneca; BMS; MSD Oncology; Roche; Takeda
Travel, Accommodations, Expenses - Roche; Takeda
 
Alain Livartowski
No Relationships to Disclose
 
Marie Ange Massiani
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; BRISTOL MYERS SQUIBB; ELIVIE; MSD; MSD; Pfizer